XRP6258-induced gene expression patterns in head and neck cancer carcinoma

Laryngoscope

Volumn 120, Issue 6, 2009, Pages 1114-1119

  Yoo, George H ^a,c   Kafri, Zyed ^a,c,d   Ensley, John F ^a,c   Lonardo, Fulvio ^a   Kim, Harold ^b,c   Folbe, Adam J ^a,c   Won, Joshua ^a,c   Stevens, Timothy ^a,c   Lin, Ho Sheng ^a,c,d  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

^c KARMANOS CANCER INSTITUTE   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Cell cycle; Novel taxoid; Taxane; XRP6258

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CYCLIN A; CYCLIN B1; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN BCL 2; TAXOID; TRANSCRIPTION FACTOR E2F1; UNCLASSIFIED DRUG; XRP 6258;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG MECHANISM; GENE EXPRESSION; HEAD AND NECK CARCINOMA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING;

ANNEXIN A5; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL CYCLE; CELL LINE, TUMOR; CYCLIN A; CYCLIN B1; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HUMANS; PHOSPHORYLATION; TAXOIDS; TUMOR CELLS, CULTURED;

EID: 77953163579     PISSN: 0023852X     EISSN: None     Source Type: Journal    
DOI: 10.1002/lary.20559     Document Type: Article

References (20)

1. Vokes EE, Weichselbaum RR, Lippman SM, Hong WK. Head and neck cancer. N Engl J Med 1993;328:184-194.
2. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. The Department of Veterans Affairs Laryngeal Cancer Study Group. N Engl J Med 1991;324:1685-1690.
3. Lefebvre JL, Chevalier D, Luboinski B, Kirkpatrick A, Collette L, Sahmoud T. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst 1996;88:890-899. (Pubitemid 26230640)
4. Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004;350:1945-1952. (Pubitemid 38580197)
5. Posner MR. Docetaxel in squamous cell cancer of the head and neck. Anticancer Drugs 2001;12(suppl 1):S21-S24. (Pubitemid 32269910)
6. Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007;357:1705-1715.
7. Vermorken JB, Remenar E, van Herpen C, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007;357:1695-1704. (Pubitemid 350005151)
8. Engels FK, Sparreboom A, Mathot RA, Verweij J. Potential for improvement of docetaxel-based chemotherapy: a pharmacological review. Br J Cancer 2005;93:173-177. (Pubitemid 41133202)
9. Bissery MC. Preclinical evaluation of new taxoids. Curr Pharm Des 2001;7:1251-1257.
10. Yoo GH, Piechocki MP, Ensley JF, et al. Docetaxel induced gene expression patterns in head and neck squamous cell carcinoma using cDNA microarray and PowerBlot. Clin Cancer Res 2002;8:3910-3921.
11. Yeudall WA, Jakus J, Ensley JF, Robbins KC. Functional characterization of p53 molecules expressed in human squamous cell carcinomas of the head and neck. Mol Carcinog 1997;18:89-96. (Pubitemid 27130267)
12. Vrignaud P, Lejeune P, Chaplin D, Lavelle F, Bissery MC. In vivo efficacy of TXD258, a new taxoid against human tumor xenografts. Presented at: 91st Annual Meeting of the American Association for Cancer Research. April 1-5, 2000; San Francisco, CA. Abstract 41.
13. Chadebech P, Truchet I, Brichese L, Valette A. Up-regulation of cdc2 protein during paclitaxel-induced apoptosis. Int J Cancer 2000;87:779-786. (Pubitemid 30660554)
14. Giannakakou P, Robey R, Fojo T, Blagosklonny MV. Low concentrations of paclitaxel induce cell type-dependent p53, p21 and G1/G2 arrest instead of mitotic arrest: molecular determinants of paclitaxel-induced cytotoxicity. Oncogene 2001;20:3806-3813. (Pubitemid 32646191)
15. Sirotnak FM, Zakowski MF, Miller VA, Scher HI, Kris MG. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 2000;6:4885-4892.
16. Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 1998;58:2825-2831. (Pubitemid 28311914)
17. Stone AA, Chambers TC. Microtubule inhibitors elicit differential effects on MAP kinase (JNK, ERK, and p38) signaling pathways in human KB-3 carcinoma cells. Exp Cell Res 2000;254:110-119.
18. Okano J, Rustgi AK. Paclitaxel induces prolonged activation of the Ras/MEK/ERK pathway independently of activating the programmed cell death machinery. J Biol Chem 2001;276:19555-19564. (Pubitemid 37411294)
19. Wang LG, Liu XM, Kreis W, Budman DR. The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a review. Cancer Chemother Pharmacol 1999; 44:355-361. (Pubitemid 29455579)
20. Piechocki MP, Lonardo F, Ensley JF, Nguyen T, Kim H, Yoo GH. Anticancer activity of docetaxel in murine salivary gland carcinoma. Clin Cancer Res 2002;8:870-877. (Pubitemid 34742120)